Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of the FSC HFA MDI in
subjects with COPD. The dose of FSC HFA MDI to be evaluated corresponds to the dose of FSC
DISKUS (250/50mcg twice-daily) that is indicated for the treatment of COPD associated with
chronic bronchitis in the US. This study will last up to approximately 15 weeks, and subjects
will visit the clinic 5 times. Subjects will be given breathing tests and will record their
peak expiratory flow measurements daily on diary cards. All study related medicines and
medical examinations will be provided at no cost. The FSC HFA MDI used in this study has been
approved by FDA for use in asthma while the FSC 250/50mcg DISKUS has been approved for use in
asthma and COPD.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Norflurane Salmeterol Xinafoate Xhance